Narcolepsy

Southern Medical Journal

Volumn 96, Issue 3, 2003, Pages 276-282

  Feldman, Neil T ^a  

^a St Petersburg Sleep Disord Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; IMIPRAMINE; METHYLPHENIDATE; MODAFINIL; OXYBATE SODIUM; PAROXETINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; CENTRAL DEPRESSANT AGENT;

AIRWAY RESISTANCE; BEHAVIOR; BREATHING DISORDER; CATAPLEXY; CLINICAL FEATURE; CONSTIPATION; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; HUMAN; HYPERSOMNIA; HYPNAGOGIC HALLUCINATION; LIMB MOVEMENT; MOTOR DYSFUNCTION; NARCOLEPSY; PARASOMNIA; PATHOPHYSIOLOGY; PHYSICIAN ATTITUDE; POLYSOMNOGRAPHY; PRIMARY MEDICAL CARE; QUESTIONNAIRE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP DISORDER; SOCIAL SUPPORT; SOMNOLENCE; SWEATING; XEROSTOMIA; ALGORITHM; HEALTH SERVICE;

ADJUVANTS, ANESTHESIA; ALGORITHMS; DIAGNOSIS, DIFFERENTIAL; HUMANS; NARCOLEPSY; SLEEP DISORDERS; SODIUM OXYBATE; VOLUNTARY HEALTH AGENCIES;

EID: 0037344014     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000056655.15660.42     Document Type: Review

References (29)

1. Hublin C, Partinen M, Kaprio J, Koskenvuo M, Guilleminault C. Epidemiology of narcolepsy. Sleep 1994;17(Suppl 8):S7-S12.
2. Moscovitch A, Partinen M, Guilleminault C. The positive diagnosis of narcolepsy and narcolepsy's borderland. Neurology 1993;43:55-60.
3. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (Orexin) receptor 2 gene. Cell 1999;98:365-376.
4. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998; 50(2 Suppl 1):S16-S22.
5. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al. Narcolepsy in Orexin knockout mice: Molecular genetics of sleep regulation. Cell 1999;98:437-451.
6. Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers GJ, Vankova J, et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001;50:381-388.
7. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6: 991-997.
8. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-474.
9. Lin L, Hungs M, Mignot E. Narcolepsy and the HLA region. J Neuroimmunol 2001;117:9-20.
10. Mignot E, Thorsby E. Narcolepsy and the HLA system. N Engl J Med 2001;344:692 (letter).
11. Krahn LE, Black JL, Silber MH. Narcolepsy: New understanding of irresistible sleep. Mayo Clin Proc 2001;76:185-194.
12. Aldrich MS. Diagnostic aspects of narcolepsy. Neurology 1998;50(2 Suppl 1):S2-S7.
13. Anic-Labat S, Guilleminault C, Kraemer HC, Meehan J, Arrigoni J, Mignot E. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 1999;22:77-87.
14. Bassetti C, Aldrich MS. Narcolepsy. Neurol Clin 1996; 14:545-571.
15. Broughton WA, Broughton RJ. Psychosocial impact of narcolepsy. Sleep 1994;17(Suppl 8):S45-S49.
16. Chaudhary BA, Husain I. Narcolepsy. J Fam Pract 1993;36:207-213.
17. Goswami M. The influence of clinical symptoms on quality of life in patients with narcolepsy. Neurology 1998;50(2 Suppl 1):S31-S36.
18. Johns MW. A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. Sleep 1991;14:540-545.
19. Mahowald MW. What is causing excessive daytime sleepiness? Evaluation to distinguish sleep deprivation from sleep disorders. Postgrad Med 2000;107:108-110, 115-118, 123.
20. Guilleminault C, Kim YD, Palombini L, Li K, Powell N. Upper airway resistance syndrome and its treatment. Sleep 2000;23(Suppl 4):S197-S200.
21. Allen RP, Earley CJ. Restless legs syndrome: A review of clinical and pathophysiologic features. J Clin Neurophysiol 2001;18:128-147.
22. Littner M, Johnson SF, McCall WV, Anderson WM, Davila D, Hartse SK, et al; Standards of Practice Committee. Practice parameters for the treatment of narcolepsy: An update for 2000. Sleep 2001;24:451-466.
23. Hublin C. Narcolepsy: Current drug treatment options. CNS Drugs 1996; 6:426-436.
24. Rogers AE, Aldrich MS, Lin X. A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep 2001;24: 385-391.
25. Broughton RJ, Fleming JA, George CF, Hill JD, Kryger MH, Moldofsky H, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49:444-451.
26. Fry JM. Treatment modalities for narcolepsy. Neurology 1998;50(2 Suppl 1):S43-S48.
27. Scrima L, Hartman PG, Johnson FH Jr, Thomas EE, Hiller FC, The effects of γ-hydroxybutyrate on the sleep of narcolepsy patients: A double-blind study. Sleep 1990;13:479-490.
28. Lammers GJ, Arends J, Declerck AC, Ferrari MD, Schouwink G, Troost J. γ-hydroxybutyrate and narcolepsy: A double-blind placebo-controlled study. Sleep 1993;16:216-220.
29. US Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42-49.